NCT00312806

Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341)

Real Life: Treatment Response in Patients With Symptoms Due to Gastroesophageal Reflux Disease Either With or Without Esophagitis Treated With Pantoprazole Sodium 40 mg o.d. Over 8 Weeks

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 2,000 (estimated)
• Sponsor: Takeda · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of the present study is to identify factors (such as symptom patterns and symptom scores) that influence the response to treatment with pantoprazole using different evaluation methods (e.g., ReQuest™ questionnaire, patient and investigator assessment). Pantoprazole will be administered once daily in the morning at one dose level. The study duration consists of a treatment period of 8 weeks. The study will provide further data on safety and tolerability of pantoprazole.

Conditions

• Gastroesophageal Reflux Disease (GERD)

Interventions

Type	Name	Description
DRUG	Pantoprazole	Pantoprazole 40 mg o.d.

Timeline

• Start date: 2006-05-01
• Primary completion: 2007-03-01
• Completion: 2007-07-01
• First posted: 2006-04-11
• Last updated: 2012-05-07

Locations

186 sites across 22 countries: Argentina, Australia, Austria, Belgium, Brazil, Canada, France, Germany, Hong Kong, India, Italy, Malaysia, Mexico, Poland, Portugal, Singapore, South Africa, South Korea, Spain, Switzerland, Taiwan, United Kingdom